Authors
Latest:
Future Therapies for ALK+ Metastatic NSCLCDr. Kim shares her insights on new investigational therapies for metastatic ALK+ NSCLC that she's particularly excited about.
Latest:
Precision Medicine in NSCLC The Power of Molecular TestingPersonalized therapy for non–small cell lung cancer has evolved significantly with the advent of comprehensive molecular testing.
Latest:
Casting a Wide NET: When Is the Optimal Time for 177Lu-Dotatate Treatment?Given that well-differentiated grade 3 NETs are relatively new, standard-of-care treatment options are undefined.
Latest:
Ensuring Quality Outcomes in Hematologic Cancer Subgroups at EHA 2024Experts discuss updated findings presented at the 2024 EHA Congress in diseases such as mantle cell lymphoma and acute myeloid leukemia.
Latest:
Cancer Network Faceoff: Conclusion of the Event and Presentation of AwardFinal remarks and presentation of awards.
Latest:
Product Profile of Amivantamab Plus Chemotherapy in EGFR Exon 20+ NSCLCTammy McClellan, PharmD, discusses the use of amivantamab plus chemotherapy in patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations.
Latest:
Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic CancerSuneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.
Latest:
Multiple Myeloma: Use of Bispecifics in Challenging Patient PopulationsBefore closing out their program on bispecifics in multiple myeloma, expert oncologists consider the value of these agents in more challenging patient populations.
Latest:
Bridging the Gaps: Taking Care of the Whole PersonSheila Lahijani, MD, FACLP, gives her perspective on the need for psycho-oncologists to help patients during their cancer journeys.
Latest:
Locoregional Liver-Directed Therapies to Treat Unresectable Colorectal Liver Metastases: A ReviewThis review article written by Nikia R. McFadden, MD, MAS, et al, discusses which therapies are best to treat unresectable colorectal liver metastases.
Latest:
Unmet Needs and Key Takeaways: ECHO Clinical TrialMedical experts evaluate unmet needs, key insights from the Phase 3 ECHO trial, and potential obstacles in integrating the findings into existing treatment protocols.
Latest:
Episode 3: Traversing the Complexities of Non-Clear Cell Renal Cell CarcinomaA brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.
